AlphaSense Strengthens Its Life Sciences Platform with Clinical Trial and Drug Data, Uniting Clinical and Regulatory Data with Trusted AI-Powered Market Intelligence

New offering connects companies, drugs, indications, trials, targets, and mode of action into a unified knowledge graph — enabling verifiable, AI-powered workflow execution for Life Sciences professionals

Key Facts (At-a-Glance):

Launch: AlphaSense is introducing Clinical Trial and Drug Data, bringing clinical, regulatory and scientific reference data — including U.S. and E.U. regulatory approvals, trial registries, drug labels, patents, and scientific reference sources spanning global markets such as the U.S., E.U., and China — directly into AlphaSense's purpose-built AI platform and knowledge graph for Life Sciences.

Capability: Life Sciences professionals can navigate this data alongside AlphaSense's proprietary and premium market content in one workflow, streamlining synthesis and handing off multi-step work — like continuous trial monitoring, competitive landscaping, or portfolio benchmarking — to SuperAnalyst, AlphaSense's always-on AI agent.

Why It Matters: Clinical Trial and Drug Data gives teams a single, trusted workspace to move from question to decision-ready output. Every answer is traceable to a source and grounded in verified clinical and regulatory evidence and domain-specific expertise.

NEW YORK — September 15, 2026 — AlphaSense, the AI platform redefining market intelligence for the business and financial world, today announced Clinical Trial and Drug Data, a suite of clinical trial and regulatory data — including U.S. and E.U. regulatory approvals, trial registries, drug labels, and patents across regions — providing an AI solution purpose-built for Life Sciences. Clinical Trial and Drug Data allows Life Sciences professionals to ask complex research questions in plain language, follow any citation into the underlying trial and approval records, and hand off multi-step research to SuperAnalyst.

AlphaSense is used today by 92% of the world's 50 largest pharmaceutical companies, including Biogen, AstraZeneca, Pfizer, and Merck.

Life Sciences professionals are under pressure to adopt AI quickly within a highly regulated, evidence-driven environment. According to Grant Thornton's 2026 AI Impact Survey, 78% of Life Sciences leaders lack strong confidence they could pass an independent AI governance audit within 90 days, a gap driven by the difficulty of applying AI in an industry where every output has to hold up to scientific and regulatory scrutiny.

For competitive intelligence teams at large pharmaceutical companies, consultants supporting portfolio and pipeline diligence, or investors evaluating biotech opportunities, that means the AI tools they use have to be as rigorous and traceable as the decisions they inform.

AlphaSense Clinical Trial and Drug Data integrates the underlying data from core clinical and regulatory databases — including clinical trial registries, drug labels, patents and exclusivity, and scientific reference sources spanning global markets such as the U.S., E.U., and China — directly into AlphaSense's knowledge graph. Combined with AlphaSense's existing library of over 500 million premium documents, 300,000 expert interview transcripts, and domain-specific AI, it provides Life Sciences teams with a single, trusted end-to-end workspace to move from initial question to decision-ready output, without toggling between multiple databases and tools.

A New Standard for Life Sciences Intelligence

Clinical Trial and Drug Data underpins four capabilities designed to give Life Science professionals faster, trusted answers to complex scientific and commercial questions:

• Unified data foundation and entity profiles: Data across pharmaceutical and biotech companies, drugs, indications, trials, targets, and mode of action is standardized from regulatory, clinical, and scientific sources into connected, instant profiles — with filterable views into pipeline assets, clinical trials, regulatory approvals, and safety data. Users can navigate this data through AlphaSense's AI instead of relying on keyword search.
• AI grounded in structured and market data: Ask complex, multi-step questions, such as “which companies are running late-stage trials in adjacent indications?” — and get a synthesized, cited answer that is built on clinical evidence and domain-specific expertise.
• Screening, charts, and export: Filter approvals and trials by target, mode of action, active ingredient, and other properties. Users can save and reuse those filters across companies — surfacing pipeline, approval, and competitive-exposure trends in interactive charts that export with one click.
• Full traceability: Every entity, record, and AI-generated answer links back to its source, so findings can be verified and used with confidence in high-stakes, regulated workflows.

“Life Sciences professionals are facing a decision problem, not a data problem,” said Sara Mallatt, Director of Healthcare Research at AlphaSense. “Adopting AI without trust introduces risk into high-stakes decisions. AlphaSense for Life Sciences closes this gap by bringing clinical data, regulatory approvals and scientific reference sources into the same environment as decision-grade intelligence. That means every insight is grounded in context and evidence. The Life Sciences organizations that move fastest from signal to conviction will win.”

Clinical Trial and Drug Data will extend what SuperAnalyst can do for Life Sciences teams — executing multi-step work like continuous trial monitoring, competitive landscaping, or portfolio benchmarking, fully grounded in verified data rather than fragmented sources. AlphaSense enables high-stakes industries to move quickly without sacrificing the rigor their decisions require.

To learn more about AlphaSense for Life Sciences and see Clinical Trial and Drug Data in action, visit here.

About AlphaSenseAlphaSense is the AI platform redefining market intelligence and workflow orchestration, trusted by thousands of leading organizations to drive faster, more confident decisions in business and finance. The platform combines domain-specific AI with a vast content universe of over 500 million premium business documents — including equity research, earnings calls, expert interviews, filings, news, and internal proprietary content. Purpose-built for speed, accuracy, and enterprise-grade security, AlphaSense helps teams extract critical insights, uncover market-moving trends, and automate complex workflows with high-quality outputs. With AI solutions like Generative Search, Generative Grid, and Deep Research, AlphaSense delivers the clarity and depth professionals need to navigate complexity and obtain accurate, real-time information quickly. For more information, visit www.alpha-sense.com.

Media Contact

Remi Duhe for AlphaSense

Email: media@alpha-sense.com